Podiatry Home
Current Issue
Archives
Supplements
Classifieds
CME
CE Articles
Subscribe
Reprints, Rights, Permission and Translation
Podiatry Today Earns Publishing Award

Dedicated to the Advancement of Footcare and Podiatry



Podiatry Today 2008 Commercial Desk Reference

View the 2008 Commercial Desk Reference for Podiatry Today
Podiatry Today

Managing Neuropathic Pain: Why Axsain Is A Viable Alternative
Technology In Practice:
Managing Neuropathic Pain: Why Axsain Is A Viable Alternative

- By Robi Garthwait, Contributing Editor


For patients suffering from neuropathic pain, quality of life can be a real issue. Traditional over-the-counter remedies have often not been enough to combat the effects of diabetic neuropathy or postherpetic neuralgia. However, with the introduction of Axsain (capsaicin 0.25%), doctors now have a new weapon in their armamentarium to fight pain.
       Used alone or as an adjunctive therapy to supplement oral medications, Axsain contains three times as much capsaicin as other brands currently on the market. It works by depleting sensory nerves of the neurotransmitter Substance P, which is involved in the transmission of pain. Axsain’s patented Lidocare vehicle also reduces the stinging side effects often associated with capsaicin treatment, according to the product’s manufacturer, Winston Laboratories.

Dr. Wu says Axsain is “a low-risk alternative for symptomatic relief” of neuropathic pain.

       Alexander Reyzelman, DPM, who has used Axsain for six months, points to many conditions that would necessitate the use of Axsain. He says these conditions include peripheral neuropathy secondary to diabetes, alcohol-induced neuropathy or any condition that results in hyperesthesia and allodynia of the extremities.
       While he notes that some patients could not tolerate the initial burning they experienced from the product, Dr. Reyzelman says the majority of the patients were pleased with Axsain.
       “Most of the patients who were able to overcome the burning pain for the first three to four days have reported a decrease in pain and were happy with the results,” notes Dr. Reyzelman, the Chairman of the Department of Medicine and an Assistant Professor at the California School of Podiatric Medicine at Samuel Merritt College.

Emphasizing Patient Education On Expectations
Doctors prescribing Axsain should inform their patients that they can expect results after repeated use. The stinging associated with the product should also lessen over time.
       “Patients need to be patient and have realistic expectations when using capsaicin cream,” explains Stephanie Wu, DPM, an Assistant Professor in the Department of Surgery at the Dr. William N. Scholl College of Podiatric Medicine at Rosalind Franklin University of Medicine and Science. “Because of Axsain’s mechanism of action, the patient needs to apply it a minimum of two to four times daily and it may take some time before the patient sees results.”
       Dr. Wu says patients often expect instantaneous results with topical medications and are quick to dismiss their effectiveness before giving them an opportunity to work.
       “Axsain is a product where patient education and awareness do play a significant role,” comments Dr. Wu, a Fellow at Scholl’s Center for Lower Extremity Ambulatory Research. “Patients should be aware that burning sensations often occur initially but generally diminish with regular use as directed.”

How The Lidocare Vehicle Helps Axsain Stand Out Over Other Topical Modalities
Dr. Reyzelman likes the fact that Axsain delivers capsaicin via the Lidocare vehicle, thus reducing the burning sensation that often accompanies capsaicin use.
       “It makes sense that the anesthetic property of lidocaine would be of benefit when combined with capsaicin,” notes Dr. Reyzelman. “In my experience, this product appears to be tolerated better by patients compared to previous similar products. If I am going to use a topical counter-irritant product, I would choose Axsain over other existing products.”
       Dr. Wu agrees. “With respect to the presently available topical preparations for painful neuralgia, Axsain stands out from the rest because of its Lidocare vehicle system,” she asserts. “Axsain is ideal in that it has minimal, if any, systemic side effects and can provide symptomatic relief in some patients.”
       Dr. Wu notes treating one patient in particular, a diabetic and kidney transplant recipient, who preferred a topical preparation over an oral medication for relief of his neuropathic pain.
       “The patient has been using Axsain for about a month and a half now and it has decreased his neuralgia from an 8 to a 2 (on the) analog pain scale,” reveals Dr. Wu, “In cases like this in which the patient is either unwilling or unable to tolerate oral medications for painful neuralgia, Axsain offers a low-risk alternative for symptomatic relief.”


Podiatry Today - ISSN: 1045-7860 - Volume 18 - Issue 7 - July 2005 - Pages: 100 -

August 29, 2008




About HMP Communications

HMP Communications LLC (HMP) is the authoritative source for comprehensive information and education servicing healthcare professionals. HMP’s products include peer-reviewed and non-peer-reviewed medical journals, national tradeshows and conferences, online programs and customized clinical programs. HMP is a wholly owned subsidiary of HMP Communications Holdings LLC, which also owns the North American Center for Continuing Medical Education (NACCME). NACCME provides a wide array of accredited CME offerings with industry thought leaders participating in roundtable meetings, webcasts, symposia, conferences, seminars, podcasts and satellite programs. Discover more about HMP’s products and services at www.hmpcommunications.com. ©2008 HMP Communications


© 2008 HMP Communications | Privacy Policy/Copyright | Contact Us